FBXL4 and prostate carcinoma: To further elucidate the role of FBXL4 in the natural history of prostate cancer, we investigated FBXL4 copy number status in the TransAtlantic Prostate Group (TAPG) cohort of conservatively managed localised prostate adenocarcinomas diagnosed by a transurethral resection of the prostate (TURP) to assess FBXL4 loss as a potential cancer prognostic biomarker.